Abstract
With the help of radiolabeled compounds, drug development can be made faster; especially with microdosing and radiopharmacokinetics, some elements of phase I and II trials necessary for conventional cancer drug development can be avoided. Imaging may proof the principle of actual targeting. However, radiopharmacokinetics is dependent on the radionuclide, the radionuclide linker with the drug and the size of the drug molecule. Optimally, some of the drug molecule atoms may be replaced with a radionuclide that can be visualized. In this article drug development utilizing radionuclides both in PET and SPET has been reviewed.
Keywords: cancer chemotherapies, radionuclide imaging, pharmacokinetics, pharmacodynamics, single photon emission tomography, positron emission tomography, cytotoxic compounds, targeting
Current Pharmaceutical Design
Title: Radiolabeled Compounds in the Development of Cytotoxic Agents
Volume: 10 Issue: 24
Author(s): Kalevi J.A. Kairemo and Marja Tahtinen
Affiliation:
Keywords: cancer chemotherapies, radionuclide imaging, pharmacokinetics, pharmacodynamics, single photon emission tomography, positron emission tomography, cytotoxic compounds, targeting
Abstract: With the help of radiolabeled compounds, drug development can be made faster; especially with microdosing and radiopharmacokinetics, some elements of phase I and II trials necessary for conventional cancer drug development can be avoided. Imaging may proof the principle of actual targeting. However, radiopharmacokinetics is dependent on the radionuclide, the radionuclide linker with the drug and the size of the drug molecule. Optimally, some of the drug molecule atoms may be replaced with a radionuclide that can be visualized. In this article drug development utilizing radionuclides both in PET and SPET has been reviewed.
Export Options
About this article
Cite this article as:
Kairemo J.A. Kalevi and Tahtinen Marja, Radiolabeled Compounds in the Development of Cytotoxic Agents, Current Pharmaceutical Design 2004; 10 (24) . https://dx.doi.org/10.2174/1381612043383458
DOI https://dx.doi.org/10.2174/1381612043383458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multi-Modal Imaging and Cancer Therapy Using Lanthanide Oxide Nanoparticles: Current Status and Perspectives
Current Medicinal Chemistry The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Recent Patents on Genetic Programming
Recent Patents on Computer Science Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) PEGylated Peptide-Based Imaging Agents for Targeted Molecular Imaging
Current Protein & Peptide Science State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Somatostatin: A Hormone for the Heart?
Current Vascular Pharmacology A Peptide Based Pro-Drug Ameliorates Amyloid-β Induced Neuronal Apoptosis in In Vitro SH-SY5Y Cells
Current Alzheimer Research Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism The Other Side of Opioid Receptor Signalling: Regulation by Protein-Protein Interaction
Current Drug Targets Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy Cellular and Biochemical Alterations Caused by Artificial Depletion of Glutathione
Current Enzyme Inhibition